New Funding Boosts URMC Biotech Start-Up for Neurological Disorders

Oscine Therapeutics, a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center has received a significant multi-year investment to support both research and development of cell-based therapies for neurological disorders. The funding represents the largest-ever investment in a URMC start-up company.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news